A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Brief summary

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

acronym

EMBRACE

status

RECRUITING

phase

PHASE3

study type

INTERVENTIONAL

enrollment

330

sponsor

Cybin IRL Limited

conditions

Major Depressive Disorder (MDD); Depression in Adults; Depression - Major Depressive Disorder; Depression Disorders; Depression Disorder; Depression

interventions

DRUG: CYB003; BEHAVIORAL: Psychological Support

start date

2025-12-10

start date type

ACTUAL

primary completion date

2027-06-07

has results

false

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters